AI Science Tracker

Max Delbrück Center for Molecular Medicine

2 discoveries from 2024 to 2026

Discoveries

Machine-learning-derived seven-protein panel distinguishes remission from active ANCA-associated vasculitis

Confounder-aware machine-learning feature selection on plasma proteomics identified a seven-protein signature—AHSG, CLEC3B, COMP, F9, LRG1, MCAM and MRC1—to classify remission versus active ANCA-associated vasculitis (AAV). After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97. In the study cohorts, the panel outperformed routine CRP and ANCA titer measurements.

Technology: MetaDeconfoundR confounder-aware feature analysis, LASSO and Boruta feature selection, and a generalized linear model applied to targeted PRM mass-spectrometry data

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: After targeted PRM mass-spectrometry assay development, a generalized linear model was evaluated in an independent cohort of 108 AAV patients and achieved AUC 0.94 (95% CI 0.90–0.98); combined discovery and validation performance was AUC 0.97.
  • Still unknown: This is cross-sectional classification of disease state in patients already diagnosed with AAV, not a prospective prediction of relapse, a validated basis for stopping immunosuppression, or evidence of improved clinical outcomes. The two cohorts together included just over 200 patients with a rare disease; the authors note uncertainty from sample size and treatment heterogeneity, and the panel remains a starting point for clinical-tool development. It is an adjunct biomarker result, not proof that the seven proteins cause remission or vasculitis activity.
  • AI role: Machine-learning methods accounted for clinical covariates including CRP, kidney function and ANCA-related measures, prioritized candidate plasma proteins, and reduced these to a seven-protein panel. Targeted PRM-MS quantified the selected proteins, and the GLM classified AAV remission versus active disease in an independent cohort. The measured validation performance and protein signature are the specific AI-enabled diagnostic finding.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42481524/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

AI-ranked SARS-CoV-2 protein interactions guide discovery of an NSP10–NSP16 inhibitor

A machine-learning classifier applied to quantitative PPI assay data and AlphaFold-Multimer predictions to prioritize SARS-CoV-2 protein interactions; 15 of 34 high-confidence interactions were not previously listed in IMEx. The team then targeted the NSP10–NSP16 methyltransferase interface in an ultra-large virtual screen. Compound 459 bound NSP10 (MST affinity about 13 μM), reduced NSP10–NSP16 interaction in cells (BRET IC50 9.2 μM), inhibited complex methyltransferase activity by about 50% at 100 μM, and reduced SARS-CoV-2 reporter replication in cells (IC50 39.5 μM).

Technology: Multi-adaptive support-vector-machine (maSVM) classifier for quantitative protein–protein interaction data, coupled with AlphaFold-Multimer complex prediction; VirtualFlow/QuickVina2 and later docking methods performed compound screening

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A machine-learning classifier applied to quantitative PPI assay data and AlphaFold-Multimer predictions to prioritize SARS-CoV-2 protein interactions; 15 of 34 high-confidence interactions were not previously listed in IMEx.
  • Still unknown: The paper reports an experimental small-molecule hit, not a drug or clinical effect. Compound 459 has micromolar affinity and cellular antiviral IC50; authors explicitly state it requires extensive optimization. Methyltransferase inhibition was about 50% at 100 μM in one initial assay; subsequent data include cellular interaction and reporter-replication experiments. The NSP10–NSP16 interface was previously known and had prior virtual screening, but this paper reports a different compound scaffold and tested outcomes; shared target does not make this a duplicate. In vitro and cell assays do not demonstrate efficacy in animals or people.
  • AI role: The maSVM algorithm prioritized PPI interactions using quantitative LuTHy binary-assay data and AlphaFold-Multimer predictions, supporting selection and mapping of SARS-CoV-2 interactions, including the NSP10–NSP16 interface and interface hot spots. The drug-like compound hit itself was identified by VirtualFlow and docking against the selected interface, not generated by the classifier. Compound 459 was then experimentally tested for protein binding, interaction disruption, methyltransferase activity and viral replication.

Evidence sources: https://link.springer.com/article/10.1038/s44320-024-00019-8

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 37 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.